Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity.
Alanine Transaminase
/ blood
Alkaline Phosphatase
/ blood
Animals
Antineoplastic Agents
/ administration & dosage
Apoptosis
Cells, Cultured
Chemical and Drug Induced Liver Injury
/ etiology
Disease Models, Animal
Humans
Inflammation
/ metabolism
Liver
/ metabolism
Male
NF-kappa B
/ metabolism
Oxidative Stress
Rats
Rats, Wistar
Sorafenib
/ administration & dosage
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
revised:
23
04
2020
accepted:
28
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
22
12
2020
Statut:
epublish
Résumé
Sorafenib is a small, orally-active multikinase inhibitor that is most frequently used for the management of renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine-resistant thyroid carcinoma. However, recent reports have associated sorafenib with hepatotoxicity that can limit its clinical application, although the mechanism of hepatotoxicity is still to be elucidated. Thus, our study was designed to explore the molecular mechanisms underlying sorafenib-induced hepatotoxicity in an
Identifiants
pubmed: 32509153
doi: 10.1155/2020/7453406
pmc: PMC7245685
doi:
Substances chimiques
Antineoplastic Agents
0
NF-kappa B
0
Sorafenib
9ZOQ3TZI87
Alanine Transaminase
EC 2.6.1.2
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7453406Informations de copyright
Copyright © 2020 Abdullah F. AlAsmari et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
BMC Complement Altern Med. 2016 Dec 3;16(1):501
pubmed: 27912738
Cancers (Basel). 2015 Sep 03;7(3):1758-84
pubmed: 26404379
Cancer Biol Ther. 2009 Oct;8(20):1904-13
pubmed: 19770576
J Infect Dis. 2003 Jun 15;187 Suppl 2:S364-9
pubmed: 12792853
J Biol Chem. 2003 May 9;278(19):16992-9
pubmed: 12624108
Dis Markers. 2018 Apr 10;2018:8473161
pubmed: 29849827
Am J Cancer Res. 2015 Aug 15;5(9):2531-61
pubmed: 26609467
Hepatogastroenterology. 2013 Mar-Apr;60(122):343-5
pubmed: 23858556
Cell. 1997 Nov 14;91(4):443-6
pubmed: 9390553
Mol Cell Biochem. 2014 Jan;385(1-2):215-23
pubmed: 24154663
Int J Mol Sci. 2019 Aug 19;20(16):
pubmed: 31430957
Mol Cancer Ther. 2008 Oct;7(10):3129-40
pubmed: 18852116
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
Eur J Pharmacol. 2006 Feb 27;532(3):290-3
pubmed: 16458885
Hepatol Int. 2016 Jan;10(1):124-32
pubmed: 26420218
Am J Physiol Gastrointest Liver Physiol. 2018 Jan 1;314(1):G97-G108
pubmed: 29025729
Br Med Bull. 1997;53(3):451-65
pubmed: 9374030
Res Pharm Sci. 2018 Oct;13(5):440-449
pubmed: 30271446
BMC Cancer. 2016 Jan 19;16:31
pubmed: 26786320
Arch Toxicol. 2017 Aug;91(8):2921-2938
pubmed: 28032146
Drug Des Devel Ther. 2016 Mar 11;10:1119-31
pubmed: 27042004
Int Immunopharmacol. 2008 Feb;8(2):362-70
pubmed: 18182252
J Am Assoc Lab Anim Sci. 2013 Jul;52(4):481-7
pubmed: 23849447
Oncogene. 2007 May 14;26(22):3291-310
pubmed: 17496923
Int J Oncol. 2014 Mar;44(3):977-85
pubmed: 24402682
Front Pharmacol. 2018 Oct 16;9:1162
pubmed: 30405405
Free Radic Res Commun. 1992;17(4):221-37
pubmed: 1473734
Hepatology. 2015 Aug;62(2):534-45
pubmed: 25902734
J Clin Oncol. 2008 Jul 10;26(20):3469-71; author reply 2471
pubmed: 18612169
Oncotarget. 2017 Apr 4;8(14):23265-23276
pubmed: 28423574
Biochem J. 2016 Dec 15;473(24):4527-4550
pubmed: 27941030
Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):216-21
pubmed: 25495944
Biomed Pharmacother. 2017 Aug;92:412-420
pubmed: 28558354
Liver Transpl. 2013 May;19(5):507-20
pubmed: 23408515
Chem Biol Interact. 2017 Jun 25;272:80-91
pubmed: 28479099
Chem Biol Interact. 2007 Dec 15;170(3):177-86
pubmed: 17850778
Mol Cancer. 2018 Feb 19;17(1):55
pubmed: 29455659
Hum Reprod. 2009 Jul;24(7):1717-25
pubmed: 19279034
Toxicol Appl Pharmacol. 2019 Nov 15;383:114768
pubmed: 31639374
Antioxidants (Basel). 2019 Dec 21;9(1):
pubmed: 31877779
Ann Surg Oncol. 2007 Feb;14(2):942-53
pubmed: 17103252
Oncogene. 1999 Nov 11;18(47):6505-12
pubmed: 10597253
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Hepatology. 2017 Jan;65(1):122-133
pubmed: 27770556
Pharmacol Rep. 2014 Dec;66(6):1050-9
pubmed: 25443734
Toxicol Mech Methods. 2013 Jun;23(5):337-45
pubmed: 23256457
Leuk Lymphoma. 2010 Feb;51(2):181-2
pubmed: 20001865
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Basic Clin Physiol Pharmacol. 2016 Sep 1;27(5):505-14
pubmed: 27226100
Toxicology. 2018 Feb 15;395:34-44
pubmed: 29341879
ACG Case Rep J. 2014 Jan 10;1(2):115-7
pubmed: 26157843
Mol Cancer Ther. 2012 Oct;11(10):2284-93
pubmed: 22902857
Pharmacol Res. 2008 Feb;57(2):125-31
pubmed: 18282716